SCHEMBL1202137

SCHEMBL1202137

[CH2]Cc1ccccc1Oc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 1/20 0.60
SLC6A4 P31645 8/20 0.58
SLC6A2 P23975 5/20 0.58
RIPK1 Q13546 1/20 0.58
CYP19A1 P11511 1/20 0.47
LTA4H P09960 1/20 0.46
TSHR P16473 1/20 0.46
HTR2A P28223 4/20 0.45
SLC6A3 Q01959 4/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
DPP4 P27487 1/20 0.43
FFAR1 O14842 1/20 0.43
MAOA P21397 1/20 0.43
PPARA Q07869 1/20 0.42
CTNNB1 P35222 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9704852 0.84 SLC6A4 (0.63) HRH1SLC6A4SLC6A2RIPK1HTR2A
SCHEMBL5545669 0.83 HRH1 (0.67) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL3334897 0.82 HRH1 (0.64) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL7646958 0.80 HRH1 (0.62) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL313132 0.80 HRH1 (0.62) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL2088976 0.79 HRH1 (0.56) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL5535030 0.79 HRH1 (0.61) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL1196716 0.78 HRH1 (0.71) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL194417 0.78 HRH1 (0.60) HRH1SLC6A4SLC6A2RIPK1CYP19A1
SCHEMBL3142433 0.78 HRH1 (0.60) HRH1SLC6A4SLC6A2RIPK1CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101528690-A Isoindoline derivatives for the treatment of arrhythmias ASTRAZENECA AB (SE) 2009-09-09 CN claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
EP-1863771-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS Transtech Pharma, Inc. (US) 2007-12-12 EP claimed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US claimed
WO-2006099379-A2 BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS TRANSTECH PHARMA, INC. (US) 2006-09-21 WO claimed
US-6723743-B1 TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS NEUROGEN CORPORATION 2004-04-20 US claimed
EP-0922050-B1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LAB (US) 2003-07-30 EP claimed
EP-0922050-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-06-16 EP claimed
US-5750510-A ANTIBIOTICS ABBOTT LABORATORIES (US) 1998-05-12 US claimed
WO-1997042205-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1997-11-13 WO claimed
US-4801721-A Stereospecific synthesis of carboxyalkyl peptides RYAN JAMES W (US) 1989-01-31 US claimed
US-4766110-A INHIBITS ANGIOTENSIN CONVERTING ENZYME, HYPOTENSIVE AGENTS RYAN JAMES W (US) 1988-08-23 US claimed
EP-0073143-B1 NOVEL COMPLEX AMIDO AND IMIDO DERIVATIVES OF CARBOXYALKYL PEPTIDES AND THIOETHERS AND ETHERS OF PEPTIDES Ryan, James Walter (US) 1985-11-21 EP claimed
EP-0073143-A2 Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides Ryan, James Walter (US) 1983-03-02 EP claimed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP claimed
US-12030970-B2 Curable composition and stereolithographic resin composition comprising same KURARAY CO., LTD. (JP) 2024-07-09 US disclosed
EP-0048159-A2 Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents UNIVERSITY OF MIAMI (US) 1982-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030970-B2 Curable composition and stereolithographic resin composition comprising same ARL1, ASH2L, VCL HRH1 2443/4885SLC6A4 4503/4885SLC6A2 4818/4885
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 HRH1 1484/4885SLC6A4 3358/4885SLC6A2 2582/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP HRH1 1627/4885SLC6A4 3984/4885SLC6A2 3624/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 HRH1 465/4885SLC6A4 2169/4885SLC6A2 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.